Provided by Tiger Fintech (Singapore) Pte. Ltd.

BiomX Inc.

0.4400
-0.0100-2.22%
Post-market: 0.44000.00000.00%18:35 EDT
Volume:167.96K
Turnover:76.61K
Market Cap:11.52M
PE:-0.21
High:0.4700
Open:0.4563
Low:0.4374
Close:0.4500
Loading ...

BiomX Inc. Releases Presentation on Clinical Stage Programs Targeting Antibiotic Resistance

Reuters
·
09 Jun

BiomX Inc. Earnings Call: Optimism and Progress

TIPRANKS
·
17 May

BiomX Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
16 May

Biomx Inc. : H.c. Wainwright Cuts Target Price to $15 From $21

THOMSON REUTERS
·
16 May

BiomX Inc. Reports Q1 2025 Progress and Financials

TIPRANKS
·
16 May

Biomx Reports First Quarter 2025 Financial Results

Reuters
·
15 May

BiomX Q1 EPS $(0.33) Beats $(0.42) Estimate

Benzinga
·
15 May

Biomx Reports First Quarter 2025 Financial Results and Provides Business and Program Updates

THOMSON REUTERS
·
15 May

Biomx Inc - Net Loss $7.7 Mln in Q1 2025

THOMSON REUTERS
·
15 May

Press Release: BiomX Reports First Quarter 2025 Financial Results and Provides Business and Program Updates

Dow Jones
·
15 May

BiomX (PHGE) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Zacks
·
18 Apr

BiomX Price Target Maintained With a $21.00/Share by HC Wainwright & Co.

Dow Jones
·
04 Apr

BiomX Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
01 Apr

Biomx Announces Compliance With Nyse Guidelines on Audit Opinion Disclosure

THOMSON REUTERS
·
01 Apr

Biomx Inc. : H.c. Wainwright Raises Target Price to $21 From $2

THOMSON REUTERS
·
01 Apr

BRIEF-BiomX Announces Positive Topline Results From Phase 2 Trial Evaluating Bx211 For The Treatment Of Diabetic Foot Osteomyelitis (DFO)

Reuters
·
31 Mar

Biomx Announces Positive Topline Results From Phase 2 Trial Evaluating Bx211 for the Treatment of Diabetic Foot Osteomyelitis (Dfo)

THOMSON REUTERS
·
31 Mar

BiomX Announces Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO)

GlobeNewswire
·
31 Mar

BiomX FY 2024 GAAP EPS $(3.36) Misses $(2.56) Estimate, BiomX's Cash Balance And Restricted Cash As Of December 31, 2024 Were $18M, Excluding The Additional $12M In Gross Proceeds Raised In The Company's February 2025 Financing Round. BiomX Estimates Its Cash, Cash Equivalents And Short-term Deposits Are Sufficient To Fund Its Operations Into Q1 Of 2026

Benzinga
·
25 Mar

BiomX Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business and Program Updates

GlobeNewswire
·
25 Mar